Nivolumab plus ipilimumab vs chemotherapy as first-line treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma: CheckMate 649 biomarker analyses

被引：2
|
作者：
Janjigian, Yelena Y.
Shitara, Kohei
Ajani, Jaffer
Moehler, Markus
Yao, Jin
Shen, Lin
Garrido, Marcelo
Gallardo, Carlos
Wyrwicz, Lucjan
Yamaguchi, Kensei
Skoczylas, Tomasz
Bragagnoli, Arinilda
Liu, Tianshu
Schenker, Michael
Yanez, Patricio
Kowalyszyn, Ruben
Karamouzis, Michalis
Zander, Thomas
Feeney, Kynan
Elimova, Elena
Nathani, Raheel
Novosiadly, Ruslan
Lei, Ming
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2023-CT037
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT037
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Health-related quality of life (HRQOL) in patients (pts) with advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC) or esophageal adenocarcinoma (EAC): Interim results of nivolumab plus chemotherapy (N plus C) versus (C) from CheckMate 649
    Moehler, M.
    Elimova, E.
    Blum, S., I
    Xiao, H.
    Davenport, E.
    Wang, J.
    Hunter, S.
    Li, M.
    Kondo, K.
    Wyrwicz, L.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 214 - 215
  • [42] EXPOSURE RESPONSE ANALYSES OF NIVOLUMAB AS ADJUVANT TREATMENT FOR PATIENTS WITH ESOPHAGEAL OR GASTROESOPHAGEAL JUNCTION CANCER (CHECKMATE 577).
    Zhao, Y.
    Tsujimoto, A.
    Ide, T.
    Zhu, L.
    Zhang, J.
    Feng, Y.
    Gao, L.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 : S60 - S60
  • [43] Adjuvant nivolumab vs placebo in resected esophageal or gastroesophageal junction cancer following neoadjuvant chemoradiotherapy: First report of comprehensive biomarker analyses from CheckMate 577
    Kelly, R.
    Moehler, M.
    Ajani, J.
    Yao, J.
    Kuzdzal, J.
    Zander, T.
    Van Cutsem, E.
    Piessen, G.
    Mendez, G.
    Feliciano, J.
    Motoyama, S.
    Lievre, A.
    Uronis, H.
    Elimova, E.
    Grootscholten, C.
    Geboes, K.
    Yang, Y.
    Zhang, J.
    Novosiadly, R.
    Cleary, J.
    Lei, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S183 - S183
  • [44] First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 Study
    Hegewisch-Becker, Susanna
    Mendez, Guillermo
    Chao, Joseph
    Nemecek, Radim
    Feeney, Kynan
    Van Cutsem, Eric
    Al-Batran, Salah-Eddin
    Mansoor, Wasat
    Maisey, Nicholas
    Pazo Cid, Roberto
    Burge, Matthew
    Perez-Callejo, David
    Hipkin, R. William
    Mukherjee, Sourav
    Lei, Ming
    Tang, Hao
    Suryawanshi, Satyendra
    Kelly, Ronan J.
    Tebbutt, Niall C.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17) : 2080 - 2093
  • [45] Updated quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of nivolumab plus chemotherapy versus chemotherapy alone as first-line (1L) treatment for advanced gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma (GC/GEJC/EAC): 4-year (yr) follow-up from CheckMate 649 (CM 649)
    Lin, Daniel
    Quan, Wenying
    Garretson, Marne
    Chirikov, Viktor
    Chen, Clara
    Singh, Prianka
    Davis, Catherine
    Sugarman, Ryan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [46] Health-related quality of life (HRQOL) in patients (pts) with advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC) or esophageal adenocarcinoma (EAC): Interim results of nivolumab plus chemotherapy (N plus C) versus (C) from CheckMate 649.
    Wyrwicz, Lucjan
    Elimova, Elena
    Blum, Steven I.
    Xiao, Hong
    Davenport, Eric
    Wang, Jinyi
    Hunter, Shannon
    Li, Mingshun
    Kondo, Kaoru
    Moehler, Markus H.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [47] Immune Checkpoint Inhibitor Plus Chemotherapy as First-Line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer: A Systematic Review and Meta-Analysis
    Zhang, Lianghui
    Huang, Lingli
    Liu, Zhixian
    Ling, Tao
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2024, 23
  • [48] Health-related quality of life (HRQOL) in patients (pts) with advanced gastric cancer/ gastroesophageal junction cancer (GC/GEJC) or esophageal adenocarcinoma (EAC): 36-month results of nivolumab plus chemotherapy (N plus C) versus (C) from CheckMate 649
    Elimova, Elena
    Wyrwicz, Lucjan
    Chen, Clara
    Blum, Steven Michael
    Davenport, Eric
    Wang, Jinyi
    Kondo, Kaoru
    Moehler, Markus H.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [49] Nivolumab plus chemotherapy for advanced gastric cancer and oesophageal adenocarcinoma
    Hindson J.
    Nature Reviews Gastroenterology & Hepatology, 2021, 18 (8) : 523 - 523
  • [50] Advanced Esophageal Cancer: Pembrolizumab plus Chemotherapy as First-line Therapy
    Franke, Katharina
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2021, 59 (12): : 1255 - +
12345